vs
Pacira BioSciences, Inc.（PCRX）与PROVIDENT FINANCIAL SERVICES INC（PFS）财务数据对比。点击上方公司名可切换其他公司
PROVIDENT FINANCIAL SERVICES INC的季度营收约是Pacira BioSciences, Inc.的1.3倍（$225.2M vs $177.4M），PROVIDENT FINANCIAL SERVICES INC净利率更高（35.3% vs 1.6%，领先33.6%），过去两年PROVIDENT FINANCIAL SERVICES INC的营收复合增速更高（17.3% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
PNC金融服务集团是总部位于美国宾夕法尼亚州匹兹堡的银行控股及金融服务企业，旗下银行子公司PNC银行业务覆盖美国27个州和华盛顿特区，拥有2629家营业网点与9523台ATM机，是美国资产规模、网点数量、存款规模、ATM保有量均位居前列的大型银行机构。
PCRX vs PFS — 直观对比
营收规模更大
PFS
是对方的1.3倍
$177.4M
净利率更高
PFS
高出33.6%
1.6%
两年增速更快
PFS
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $225.2M |
| 净利润 | $2.9M | $79.4M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | — |
| 净利率 | 1.6% | 35.3% |
| 营收同比 | 5.0% | — |
| 净利润同比 | — | 24.0% |
| 每股收益（稀释后） | $0.07 | $0.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXPFS
| Q1 26 | $177.4M | $225.2M | ||
| Q4 25 | $196.9M | $225.7M | ||
| Q3 25 | $179.5M | $221.8M | ||
| Q2 25 | $181.1M | $214.2M | ||
| Q1 25 | $168.9M | $208.8M | ||
| Q4 24 | $187.3M | $205.9M | ||
| Q3 24 | $168.6M | $210.6M | ||
| Q2 24 | $178.0M | $163.8M |
净利润PCRXPFS
| Q1 26 | $2.9M | $79.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $71.7M | ||
| Q2 25 | $-4.8M | $72.0M | ||
| Q1 25 | $4.8M | $64.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $46.4M | ||
| Q2 24 | $18.9M | $-11.5M |
毛利率PCRXPFS
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXPFS
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 49.7% | ||
| Q3 25 | 3.5% | 45.8% | ||
| Q2 25 | 4.7% | 47.8% | ||
| Q1 25 | 1.2% | 44.0% | ||
| Q4 24 | 13.2% | 30.5% | ||
| Q3 24 | -82.8% | 31.0% | ||
| Q2 24 | 15.9% | -13.0% |
净利率PCRXPFS
| Q1 26 | 1.6% | 35.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 32.3% | ||
| Q2 25 | -2.7% | 33.6% | ||
| Q1 25 | 2.8% | 30.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 22.0% | ||
| Q2 24 | 10.6% | -7.0% |
每股收益（稀释后）PCRXPFS
| Q1 26 | $0.07 | $0.61 | ||
| Q4 25 | $0.05 | $0.64 | ||
| Q3 25 | $0.12 | $0.55 | ||
| Q2 25 | $-0.11 | $0.55 | ||
| Q1 25 | $0.10 | $0.49 | ||
| Q4 24 | $0.38 | $0.37 | ||
| Q3 24 | $-3.11 | $0.36 | ||
| Q2 24 | $0.39 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $222.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $2.9B |
| 总资产 | $1.2B | $25.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXPFS
| Q1 26 | $144.3M | $222.1M | ||
| Q4 25 | $238.4M | $209.1M | ||
| Q3 25 | $246.3M | $299.2M | ||
| Q2 25 | $445.9M | $258.0M | ||
| Q1 25 | $493.6M | $234.1M | ||
| Q4 24 | $484.6M | $205.9M | ||
| Q3 24 | $453.8M | $244.0M | ||
| Q2 24 | $404.2M | $290.5M |
总债务PCRXPFS
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXPFS
| Q1 26 | $653.9M | $2.9B | ||
| Q4 25 | $693.1M | $2.8B | ||
| Q3 25 | $727.2M | $2.8B | ||
| Q2 25 | $757.8M | $2.7B | ||
| Q1 25 | $798.5M | $2.7B | ||
| Q4 24 | $778.3M | $2.6B | ||
| Q3 24 | $749.6M | $2.6B | ||
| Q2 24 | $879.3M | $2.6B |
总资产PCRXPFS
| Q1 26 | $1.2B | $25.2B | ||
| Q4 25 | $1.3B | $25.0B | ||
| Q3 25 | $1.3B | $24.8B | ||
| Q2 25 | $1.5B | $24.5B | ||
| Q1 25 | $1.6B | $24.2B | ||
| Q4 24 | $1.6B | $24.1B | ||
| Q3 24 | $1.5B | $24.0B | ||
| Q2 24 | $1.6B | $24.1B |
负债/权益比PCRXPFS
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PFS
| Net Interest Income | $193.7M | 86% |
| Noninterest Income | $31.5M | 14% |
